Financial Tearsheet

Company Overview

Recent Financial News

Date   Headline
Oct 17, 2019 Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study
Oct 16, 2019 Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17
Oct 14, 2019 Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio
Oct 14, 2019 Aytu BioScience Announces $10 Million Private Placement
Oct 02, 2019 Aytu BioScience and Validus Pharmaceuticals Announce ZolpiMist Co-Promotion Agreement and Launch Into the $163 Million Psychiatry Market

IR Contacts

Hayden IR

James Carbonara
1441 Broadway
Fifth Floor
New York, NY 10018
Office: (646)-755-7412
James@haydenir.com

Stock Performance

Today's Open 1.20
Volume 112,118
Day Range 1.13 - 1.23
52 Week Range 0.68 - 2.61
Bid/Ask 1.22 / 1.20
Bid/Ask Size 5,900 X 300
Previous Close 1.23
Market Cap 21.05 million
Shares Outstanding 17.69 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -4.002300
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Sep 26, 2019 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2019 10-Q/A Quarterly report (Amendment) htmlhtml   pdfpdf   xbrlxbrl  
Feb 07, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Nov 07, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Josh Disbrow, Chairman & Chief Executive Officer

Jarrett Disbrow, Chief Operating Officer

David Green, Chief Financial Officer

Board of Directors

Josh Disbrow, Chairman & Chief Executive Officer

Gary Cantrell, Director, Chair, Compensation Committee

Carl Dockery, Director, Chair, Nominating & Governance Committee

John Donofrio, Jr., Director, Chair, Audit Committee

Michael Macaluso, Director